company background image
IMVT

ImmunovantNasdaqGS:IMVT Stock Report

Market Cap

US$1.0b

7D

4.4%

1Y

-75.2%

Updated

28 Sep, 2021

Data

Company Financials +
IMVT fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMVT Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Immunovant
Historical stock prices
Current Share PriceUS$9.03
52 Week HighUS$6.68
52 Week LowUS$53.75
Beta0
1 Month Change7.50%
3 Month Change-14.57%
1 Year Change-75.23%
3 Year Changen/a
5 Year Changen/a
Change since IPO-43.44%

Recent News & Updates

Jun 20
We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Shareholder Returns

IMVTUS BiotechsUS Market
7D4.4%-0.3%2.0%
1Y-75.2%23.8%32.8%

Return vs Industry: IMVT underperformed the US Biotechs industry which returned 23.8% over the past year.

Return vs Market: IMVT underperformed the US Market which returned 32.8% over the past year.

Price Volatility

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Beta0
Industry Beta1.03
Market Beta1

Stable Share Price: IMVT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: IMVT's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a68Pete Salzmannhttps://immunovant.com

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York.

Immunovant Fundamentals Summary

How do Immunovant's earnings and revenue compare to its market cap?
IMVT fundamental statistics
Market CapUS$1.04b
Earnings (TTM)-US$111.19m
Revenue (TTM)n/a

0x

P/S Ratio

-9.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMVT income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$111.19m
Earnings-US$111.19m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.97
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMVT perform over the long term?

See historical performance and comparison

Valuation

Is Immunovant undervalued compared to its fair value and its price relative to the market?

2.84x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IMVT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IMVT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMVT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: IMVT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMVT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMVT is good value based on its PB Ratio (2.8x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Immunovant forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

10.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMVT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMVT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMVT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMVT is forecast to have no revenue next year.

High Growth Revenue: IMVT is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IMVT is forecast to be unprofitable in 3 years.


Past Performance

How has Immunovant performed over the past 5 years?

-8.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IMVT is currently unprofitable.

Growing Profit Margin: IMVT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMVT is unprofitable, and losses have increased over the past 5 years at a rate of 8.7% per year.

Accelerating Growth: Unable to compare IMVT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMVT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: IMVT has a negative Return on Equity (-30.42%), as it is currently unprofitable.


Financial Health

How is Immunovant's financial position?


Financial Position Analysis

Short Term Liabilities: IMVT's short term assets ($384.8M) exceed its short term liabilities ($20.5M).

Long Term Liabilities: IMVT's short term assets ($384.8M) exceed its long term liabilities ($2.0M).


Debt to Equity History and Analysis

Debt Level: IMVT is debt free.

Reducing Debt: IMVT had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMVT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IMVT has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 2.3% each year.


Dividend

What is Immunovant current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMVT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMVT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMVT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMVT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMVT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Pete Salzmann (53 yo)

2.25yrs

Tenure

US$15,375,304

Compensation

Dr. Peter Salzmann, also known as Pete, M.D., M.B.A. is the Chief Executive Officer of Immunovant, Inc. since June 2019 and has been its Director since December 2019. Dr. Salzmann serves as Independent Dir...


CEO Compensation Analysis

Compensation vs Market: Pete's total compensation ($USD15.38M) is above average for companies of similar size in the US market ($USD2.28M).

Compensation vs Earnings: Pete's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IMVT's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: IMVT's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: IMVT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.2%.


Top Shareholders

Company Information

Immunovant, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Immunovant, Inc.
  • Ticker: IMVT
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.038b
  • Shares outstanding: 115.00m
  • Website: https://immunovant.com

Number of Employees


Location

  • Immunovant, Inc.
  • 320 West 37th Street
  • New York
  • New York
  • 10018
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/28 23:28
End of Day Share Price2021/09/28 00:00
Earnings2021/06/30
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.